Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. (13th September 2016)

• Record Type: Journal Article
• Authors: Shields, Ryan K.; Potoski, Brian A.; Haidar, Ghady; Hao, Binghua; Doi, Yohei; Chen, Liang; Press, Ellen G.; Kreiswirth, Barry N.; Clancy, Cornelius J.; Nguyen, M. Hong
• Is Part Of: Clinical infectious diseases. Volume 63:Number 12(2016)
• Page Start: 1615
• Page End: 1618
• Publication Date: 2016-09-13
• Subjects: ceftazidime-avibactam resistance -- carbapenem-resistant Enterobacteriaceae -- Klebsiella pneumoniae carbapenemase; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciw636
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.